Vascular endothelial growth factor gene therapy - HSCI

Drug Profile

Vascular endothelial growth factor gene therapy - HSCI

Alternative Names: Neovasculgen; PI-VEGF165; VEGF gene therapy - HSCI

Latest Information Update: 07 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Human Stem Cells Institute
  • Class Gene therapies; Ischaemic heart disorder therapies; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inducing agents; Vascular endothelial growth factor A expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Peripheral arterial disorders
  • Clinical Phase Unknown Diabetic foot ulcer

Most Recent Events

  • 01 Aug 2015 Clinical trials in Diabetic foot ulcer in Russia (IM)
  • 05 Feb 2015 Human Stem Cell Institute plans a phase I/II trial for Peripheral nerve injuries (Adjuvant therapy) in Russia (NCT02352649)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top